TOP HEADLINES

Featured Story

  • New COO engineers a management shake-up at Takeda

    Takeda didn't bring on non-Japanese COO Christophe Weber for nothing. The Osaka-based drugmaker, still faltering in the wake of its patent loss on diabetes champ Actos, was looking for a shake-up. And now, as promised, the blueprints for a new, reorganized company structure are here. Read more >>

Allergan, Valeant agree on meeting date. Now, the fight for shareholder votes

After months of battling between Allergan and its pursuers, Valeant and Pershing Square Capital Management, the two sides have reached a truce--at least when it comes to an upcoming shareholder meeting.

UPDATED: With FDA confab looming, Chantix experts can't persuade court to unseal Pfizer records

Next month, the FDA's expert advisers will take another look at Pfizer's stop-smoking drug Chantix. The official agenda: Weigh new data on Chantix's links to psychiatric side effects, and consider changing the black-box warning about those risks.

Switzerland wants to slash drug prices? Not so fast, say Novartis and Roche

So much for home field advantage. Switzerland plans to put the squeeze on drug prices, despite its corporate citizens Roche and Novartis. And the Basel-based companies are none too happy about the idea.

Roche says fake MabThera has surfaced in EU

Roche is again tracking down counterfeits of some of its cancer meds in Europe after an importer in Germany discovered the fakes. In this case, it is counterfeit MabThera, sold as Rituxan in the U.S.

Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them

Remember all those industrial and investment promises Pfizer made when it was trying to snag AstraZeneca earlier this year? The body that polices U.K. dealmaking is eyeing new rules that would give it more power to enforce such promises, should Pfizer--or another company--come calling in the future.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Avinger has raised $35 million toward its ongoing U.S. pivotal trial of a lumivascular catheter that combines intravascular imaging with arterial plaque removal. The total target for this financing is $49 million and 65 undisclosed investors have participated thus far, according to an SEC filing.

FierceDiagnostics

Alzheimer's watchers are left for the moment focusing on small victories. Amarantus Bioscience Holdings recently accomplished one, completing enrollment in a planned study of 72 patients to assess the feasibility of LymPro, its Alzheimer's blood diagnostic test.